The effect of tissue plasminogen activator on premacular hemorrhage
- PMID: 11195747
The effect of tissue plasminogen activator on premacular hemorrhage
Abstract
Background and objective: Early vitrectomy is recommended for eyes with premacular hemorrhage, which causes fibrovascular proliferation and macular traction. The purpose of this study was to investigate the therapeutic effects of tissue plasminogen activator (tPA) on premacular hemorrhage, and the clearing of hemorrhage from the macula.
Patients and methods: The authors injected tPA (25-37.5 microg) into the vitreous cavity of 13 eyes with premacular hemorrhage. The causes of premacular hemorrhage were diabetic retinopathy in 11 eyes and traumatic injuries in 2 eyes. Prior to tPA injection, 4 eyes had complete posterior vitreous detachment (PVD) and 9 eyes had no PVD.
Results: After tPA injection, the hemorrhages in 10 eyes were completely absorbed. They were absorbed partially in 2 eyes and were not absorbed at all in 1 eye. Absorption of hemorrhage in the 4 eyes with complete PVD took an average of 5.5 days, and in the 6 eyes with no PVD, it took an average of 12.7 days (P=0.002). After tPA injection, visual acuity improved in 9 eyes, remained stable in 3 eyes, and worsened in 1 eye. In 5 eyes, pars plana vitrectomy (PPV) was required after tPA injection because of recurrent vitreous hemorrhage, macular traction or nonabsorbed premacular hemorrhage.
Conclusion: TPA seems to be a good alternative method of treatment for premacular hemorrhage, especially in eyes with complete PVD. It appears to improve vision and defer the need for PPV.
Similar articles
-
Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement.Ophthalmology. 1999 Oct;106(10):1900-6; discussion 1906-7. doi: 10.1016/S0161-6420(99)90399-8. Ophthalmology. 1999. PMID: 10519583 Clinical Trial.
-
Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy.Ger J Ophthalmol. 1995 Nov;4(6):323-7. Ger J Ophthalmol. 1995. PMID: 8751095 Clinical Trial.
-
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].Zhonghua Yan Ke Za Zhi. 1995 Jul;31(4):255-8. Zhonghua Yan Ke Za Zhi. 1995. PMID: 8745515 Chinese.
-
Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review.Ophthalmology. 2003 Apr;110(4):704-8. doi: 10.1016/S0161-6420(02)01979-6. Ophthalmology. 2003. PMID: 12689889 Review.
-
[Using enzymes in the posterior eye segment. Current status and future possibilities].Ophthalmologe. 2001 Dec;98(12):1176-80. doi: 10.1007/s003470170010. Ophthalmologe. 2001. PMID: 11799901 Review. German.
Cited by
-
Outcomes of Nd:YAG Laser Posterior Membranotomy in the Treatment of Macular Preretinal Hemorrhage: A Systematic Review and Meta-Analysis.J Vitreoretin Dis. 2025 Aug 22:24741264251364824. doi: 10.1177/24741264251364824. Online ahead of print. J Vitreoretin Dis. 2025. PMID: 40881462 Free PMC article. Review.
-
Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation.Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1547-51. doi: 10.1007/s00417-008-0902-8. Epub 2008 Aug 6. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 18682973
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous